Neuroleptics and mortality in schizophrenia: Prospective analysis of deaths in a French cohort of schizophrenic patients

Schizophrenia Research

Volumn 57, Issue 2-3, 2002, Pages 147-156

  Montout, Christine ^a   Casadebaig, Francoise ^b   Lagnaoui, Rajaa ^a   Verdoux, Helene ^a   Philippe, Alain ^b   Begaud, Bernard ^a   Moore, Nicholas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

Author keywords

Causes of death; Classes of neuroleptic; Schizophrenia; Thioxanthenes

Indexed keywords

ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; THIOXANTHENE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANCER; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; FEMALE; FOLLOW UP; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUICIDE; VASCULAR DISEASE;

EID: 0036773659     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00325-5     Document Type: Article

References (29)

1. Adamantidis M.M., Kerram P., Dupuis B.A. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam. Clin. Pharmacol. 8:1994;391-407.
2. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr. Bull. 15:1989;81-89.
3. Anon. Dictionnaire Vidal: Classement des Spécialités Pharmaceutiques. 2000;OVP, Paris.
4. Appleby L., Thomas S., Ferrier N., Lewis G., Shaw J., Amos T. Sudden unexplained death in psychiatric in-patients. Br. J. Psychiatry. 176:2000;405-406.
5. Black D.W., Fisher R. Mortality in DSM-IIIR schizophrenia. Schizophr. Res. 7:1992;109-116.
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry. 171:1997;502-508.
7. Casadebaig F., Philippe A. [Mortality in schizophrenic patients. 3 years follow-up of a cohort]. Encephale. 25:1999;329-337.
8. Coodin S., Ballegeer T. Clozapine therapy and pulmonary embolism. Can. J. Psychiatry. 45:2000;395.
9. Drici M.D., Wang W.X., Liu X.K., Woosley R.L., Flockhart D.A. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J. Clin. Psychopharmacol. 18:1998;477-481.
10. Ewing J.A. Detecting alcoholism. The CAGE questionnaire. Jama. 252:1984;1905-1907.
11. Fourrier A., Gasquet I., Allicar M.P., Bouhassira M., Lepine J.P., Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br. J. Clin. Pharmacol. 49:2000;80-86.
12. Ganguli R. Weight gain associated with antipsychotic drugs. J. Clin. Psychiatry. 60:1999;20-24.
13. Ginestet D. Guide du bon Usage des Psychotropes. 1997;Doin Editeurs, Paris.
14. Hagg S., Spigset O., Soderstrom T.G. Association of venous thromboembolism and clozapine. Lancet. 355:2000;1155-1156.
15. Harris E.C., Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry. 170:1997;205-228.
16. Harris E.C., Barraclough B. Excess mortality of mental disorder. Br. J. Psychiatry. 173:1998;11-53.
17. Heikkila L., Eliander H., Vartiainen H., Turunen M., Pedersen V. Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multi-centre study. Curr. Med. Res. Opin. 12:1992;594-603.
18. Hosmer D.W., Lemeshaw S. Applied Logistic Regression. 1989;Wiley, Chichester.
19. Jablensky A. Schizophrenia: recent epidemiologic issues. Epidemiol. Rev. 17:1995;10-20.
20. James W.P. The epidemiology of obesity. Ciba Found. Symp. 201:1996;1-11.
21. Kawachi I. Physical and psychological consequences of weight gain. J. Clin. Psychiatry. 60:1999;5-9.
22. Lissner L., Johansson S.E., Qvist J., Rossner S., Wolk A. Social mapping of the obesity epidemic in Sweden. Int. J. Obes. Relat. Metab. Disord. 24:2000;801-805.
23. Modestin J., Krapf R., Boker W. A fatality during haloperidol treatment: mechanism of sudden death. Am. J. Psychiatry. 138:1981;1616-1617.
24. Montgomery S.A. Suicide and antidepressants. Ann. N. Y. Acad. Sci. 836:1997;329-338.
25. Mortensen P.B., Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr. Scand. 81:1990;372-377.
26. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 45:2000;21-28.
27. Rossau C.D., Mortensen P.B. Risk factors for suicide in patients with schizophrenia: nested case- control study. Br. J. Psychiatry. 171:1997;355-359.
28. Taiminen T.J., Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid in patients. A controlled retrospective study. Acta Psychiatr. Scand. 90:1994;247-251.
29. Waddington J.L., Youssef H.A., Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br. J. Psychiatry. 173:1998;325-329.